Pyrazole derivatives as protein kinase modulators

Patent metadata

Field	Value
Publication number	US-9283226-B2
Application number	US-201414180440-A
Country	US
Kind code	B2
Filing date	Feb 14, 2014
Priority date	Dec 23, 2003
Publication date	Mar 15, 2016
Grant date	Mar 15, 2016

Abstract

The invention provides compounds of the formula (I) having protein kinase B inhibiting activity:

wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R 1 and NR 2 R 3 and a maximum chain length of 4 atoms extending between E and NR 2 R 3 , wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom α with respect to the NR 2 R 3 group and provided that the oxo group when present is located at a carbon atom α with respect to the NR 2 R 3 group;
E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R 1 is an aryl or heteroaryl group; and R 2 , R 3 , R 4 and R 5 are as defined in the claims.

Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.

First claim

The invention claimed is:

1. A method of inhibiting protein kinase A (PKA) or protein kinase B (PKB), the method comprising contacting the PKA or PKB with a compound having the formula (IV):

or a salt, solvate, or tautomer thereof,
wherein z is 0, 1 or 2;
R 1 is unsubstituted phenyl or phenyl substituted with 1, 2, 3 or 4 substituents independently selected from hydroxy, C 1-4 acyloxy, fluorine, chlorine, bromine, trifluoromethyl, cyano, C 1-4 hydrocarbyloxy and C 1-4 hydrocarbyl optionally substituted by C 1-2 alkoxy or hydroxy;
R 2 and R 3 are independently selected from hydrogen and methyl;
R 4 is selected from hydrogen and methyl;
R 5 is selected from hydrogen and methyl; and
R 20 is selected from hydrogen, methyl, hydroxy and fluorine, provided that when z is 0,
R 20 is other than hydroxy.

2. A combination comprising:
a compound having the formula (IV):

or a salt, solvate, or tautomer thereof,
wherein z is 0, 1 or 2;
R 1 is unsubstituted phenyl or phenyl substituted with 1, 2, 3 or 4 substituents independently selected from hydroxy, C 1-4 acyloxy, fluorine, chlorine, bromine, trifluoromethyl, cyano, C 1-4 hydrocarbyloxy and C 1-4 hydrocarbyl optionally substituted by C 1-2 alkoxy or hydroxy;
R 2 and R 3 are independently selected from hydrogen and methyl;
R 4 is selected from hydrogen and methyl;
R 5 is selected from hydrogen and methyl; and
R 20 is selected from hydrogen, methyl, hydroxy and fluorine, provided that when z is 0, R 20 is other than hydroxy, and
one or more other therapeutic agents.

3. A combination according to claim 2 wherein at least one of the one or more other therapeutic agents is selected from:
Topoisomerase I inhibitors;
Antimetabolites;
Tubulin targeting agents;
DNA binder and topoisomerase II inhibitors;
Alkylating Agents;
Monoclonal Antibodies;
Anti-Hormones;
Signal Transduction Inhibitors;
Proteasome Inhibitors;
DNA methyl transferases; and
Cytokines and retinoids.

4. A combination according to claim 2 wherein the group R 1 has one or two substituents selected from fluorine, chlorine, trifluoromethyl, methyl and methoxy.

5. A combination according to claim 4 wherein R 1 is a mono-chlorophenyl or dichlorophenyl group.

6. A combination according to claim 2 wherein R 2 and R 3 are both hydrogen.

7. A combination according to claim 2 comprising a compound which is:
2-phenyl-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethylamine;
2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)-phenyl]-2-phenyl-ethylamine;
2-(4-chloro-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethylamine;
{3-(4-chloro-phenyl)-3-[4-(1H-pyrazol-4-yl)-phenyl]-propyl}-methyl-amine;
{3-(3,4-difluoro-phenyl)-3-[4-(1H-pyrazol-4-yl)-phenyl]-propyl}-methyl-amine;
{3-(3-chloro-phenyl)-3-[4-(1H-pyrazol-4-yl)-phenyl]-propyl}-methyl-amine;
3-(4-chloro-phenyl)-3-[4-(1H-pyrazol-4-yl)-phenyl]-propylamine;
3-(3,4-dichloro-phenyl)-3-[4-(1H-pyrazol-4-yl)-phenyl]-propylamine;
{2-(4-chloro-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethyl}-dimethyl-amine;
{2-(4-chloro-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethyl}-methyl-amine;
{2-(4-chloro-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethyl}-methyl-amine (R);
{2-(4-chloro-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethyl}-methyl-amine (S);
dimethyl-{2-phenyl-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethyl}-amine;
2-(4-chloro-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethylamine (R);
2-(4-chloro-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethylamine (S);
{2-(4-chloro-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethyl}-methyl-amine;
{2-(4-methoxy-phenyl)-2-[4-(1-pyrazol-4-yl)-phenyl]-ethyl}-methyl-amine;
{3-(4-fluoro-phenyl)-3-[4-(1H-pyrazol-4-yl)-phenyl]-propyl}-methyl-amine;
{2-(4-fluoro-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethyl}-methyl-amine;
{2-(3-chloro-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethyl}-methyl-amine;
4-{3-methylamino-1-[4-(1H-pyrazol-4-yl)-phenyl]-propyl}-phenol;
3-(4-methoxy-phenyl)-3-[4-(1H-pyrazol-4-yl)-phenyl]-propylamine;
{2-(4-chloro-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-propyl}-methyl-amine;
1-(4-chloro-phenyl)-2-methylamino-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol;
2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol;
3-(3-chloro-phenyl)-3-[4-(1H-pyrazol-4-yl)-phenyl]-propylamine;
2-(3-chloro-4-methoxy-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethylamine;
2-(4-chloro-phenyl)-2-fluoro-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethylamine;
2-(4-chloro-3-fluoro-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethylamine;
2-(3,4-dichloro-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethylamine;
{2-(3-chloro-4-methoxy-phenyl)-2-[4-(1H-pyrazol-4-yl)-phenyl]-ethyl}-methyl-amine;
3-(3-chloro-4-methoxy-phenyl)-3-[4-(1H-pyrazol-4-yl)-phenyl]-propylamine; or
C-(4-chloro-phenyl)-C-[4-(1H-pyrazol-4-yl)-phenyl]-methylamine;
or a salt, solvate, or tautomer thereof.

8. A combination according to claim 2 wherein the compound is in the form of a salt.

9. A combination according to claim 2 wherein the compound is 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol or a salt or tautomer thereof.

10. A combination according to claim 9 wherein the compound is a salt of 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol.

11. A combination according to claim 10 wherein the compound is in the form of a hydrochloride salt.

12. A combination according to claim 11 wherein the compound is in the form of a dihydrochloride salt.

13. A combination according to claim 2 wherein the compound having the formula (IV), or the salt, solvate, or tautomer thereof, and the one or more other therapeutic agents are formulated together in a dosage form.

14. A combination according to claim 13 wherein the compound is 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol or a salt or tautomer thereof.

15. A combination according to claim 14 wherein the compound is in the form of a hydrochloride salt.

16. A combination according to claim 15 wherein the compound is in the form of a dihydrochloride salt.

17. A combination according to claim 2 wherein the compound having the formula (IV), or the salt, solvate, or tautomer thereof, and the one or more other therapeutic agents are formulated separately and presented together in the form of a kit.

18. A combination according to claim 17 wherein the compound is 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol or a salt or tautomer thereof.

19. A combination according to claim 18 wherein the compound is in the form of a hydrochloride salt.

20. A combination according to claim 19 wherein the compound is in the form of a dihydrochloride salt.

Assignees

• Astex Therapeutics Ltd
• Cancer Res Inst Royal
• Cancer Rec Tech Ltd
• Astex Therapeutics Ltd

Inventors

• Berdini Valerio
• Saxty Gordon
• Verdonk Marinus Leendert
• Woodhead Steven John
• Wyatt Paul Graham
• Boyle Robert George
• Sore Hannah Fiona
• Walker David Winter
• Collins Ian
• Downham Robert
• Carr Robin Arthur Ellis

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title